Dr Reddy's Laboratories Free Cash Flow 2010-2023 | RDY

Dr Reddy's Laboratories annual/quarterly free cash flow history and growth rate from 2010 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
  • Dr Reddy's Laboratories free cash flow for the quarter ending December 31, 2023 was 286.00, a year-over-year.
  • Dr Reddy's Laboratories free cash flow for the twelve months ending December 31, 2023 was , a year-over-year.
  • Dr Reddy's Laboratories annual free cash flow for 2023 was $0.579B, a 218.13% increase from 2022.
  • Dr Reddy's Laboratories annual free cash flow for 2022 was $0.182B, a 48.88% decline from 2021.
  • Dr Reddy's Laboratories annual free cash flow for 2021 was $0.356B, a 6.59% increase from 2020.
Dr Reddy's Laboratories Annual Free Cash Flow
2023 579.00
2022 182.00
2021 356.00
2020 334.00
2019 332.00
2018 136.00
2017 144.00
2016 443.00
2015 255.00
2014 157.00
2013 123.00
2012 183.00
2011 -16.00
2010 203.00
2009 3.00
Dr Reddy's Laboratories Quarterly Free Cash Flow
2023-12-31 286.00
2023-09-30 269.00
2023-06-30 93.00
2023-03-31 579.00
2022-12-31 369.00
2022-09-30 126.00
2022-06-30 44.00
2022-03-31 182.00
2021-12-31 111.00
2021-09-30 -67.08
2021-06-30 -88.00
2021-03-31 356.00
2020-12-31 242.00
2020-09-30 220.00
2020-06-30 124.00
2020-03-31 334.00
2019-12-31 340.00
2019-09-30 256.00
2019-06-30 133.00
2019-03-31 332.00
2018-12-31 271.00
2018-09-30 45.00
2018-06-30 -102.00
2018-03-31 136.00
2017-12-31 71.00
2017-09-30 -12.00
2017-06-30 -74.00
2017-03-31 144.00
2016-12-31 56.00
2016-09-30 22.00
2016-06-30 27.00
2016-03-31 443.00
2015-12-31 352.00
2015-09-30 220.00
2015-06-30 95.00
2015-03-31 255.00
2014-12-31 125.00
2014-09-30 79.00
2014-06-30 42.00
2014-03-31 157.00
2013-12-31 56.00
2013-09-30 -5.00
2013-06-30 42.00
2013-03-31 123.00
2012-12-31 105.82
2012-09-30 69.00
2012-06-30 36.00
2012-03-31 183.00
2011-12-31 83.00
2011-09-30 14.00
2011-06-30 24.00
2011-03-31 -16.00
2010-12-31 11.49
2010-09-30 -15.05
2010-06-30 -23.00
2010-03-31 203.00
2009-12-31 198.00
2009-09-30 151.19
2009-06-30 81.00
2009-03-31 3.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.932B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $17.646B 6.15
Aspen Pharmacare (APNHY) South Africa $5.386B 0.00
BridgeBio Pharma (BBIO) United States $5.183B 0.00
Bausch Health Cos (BHC) Canada $2.579B 1.96
Amphastar Pharmaceuticals (AMPH) United States $2.030B 12.41
Supernus Pharmaceuticals (SUPN) United States $1.721B 0.00
Taysha Gene Therapies (TSHA) United States $0.445B 0.00
Generation Bio (GBIO) United States $0.206B 0.00
Personalis (PSNL) United States $0.079B 0.00
Assembly Biosciences (ASMB) United States $0.070B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00